Prestige Consumer Healthcare Inc. (PBH) - Q3 2025 (Ended Dec 31, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the third quarter and nine-month period ended December 31, 2024, for Prestige Consumer Healthcare Inc. (Prestige). The company develops, manufactures, and markets over-the-counter (OTC) healthcare products in North America and international markets. The fiscal year ends March 31; therefore, this report represents the first nine months of fiscal year 2025.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $290.3 million | $282.7 million | $841.2 million | $848.4 million |
| Net Income | $61.0 million | $53.0 million | $164.5 million | $159.9 million |
| Diluted EPS | $1.22 | $1.06 | $3.28 | $3.19 |
| Gross Margin | 55.5% | 55.9% | 55.2% | 55.7% |
| Operating Income | $92.0 million | $86.8 million | $248.3 million | $260.3 million |
| Operating Cash Flow (YTD) | $189.7 million (vs. $182.0 million YTD 2023) | |||
| Long-Term Debt (Net) | $992.0 million (as of Dec 31, 2024) | |||
| Cash & Equivalents | $50.9 million (as of Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenues increased 2.7% year-over-year, driven by an 11.3% increase in International OTC Healthcare sales (primarily Gastrointestinal) and a 1.0% increase in North American sales. However, YTD revenues declined 0.8% due to decreases in North American Cough & Cold, Women's Health, and Oral Care categories.
- Profitability: Net income rose 15.1% in Q3 and 2.9% YTD. The effective tax rate decreased to 21.8% YTD (from 23.4% prior year) due to the release of a reserve for uncertain tax positions.
- Debt Reduction: The company fully repaid its $135 million 2012 Term B-5 Loan during Q3. Total outstanding indebtedness is now $1.0 billion, consisting solely of senior notes.
- Margin Pressure: Gross margins declined slightly in both Q3 and YTD periods, attributed to increased supply chain costs and product mix shifts.
Outlook, Risks, and Management Commentary
- Supply Chain Challenges: Management cites ongoing global supply chain constraints, labor shortages, and raw material cost inflation. Specific shortages in eye care products have negatively impacted sales, with expectations of further disruptions.
- Acquisition Activity: On October 1, 2024, the company acquired intellectual property rights for Hydralyte in jurisdictions outside the U.S. for approximately $8.3 million.
- Share Repurchases: Under a $300 million authorization approved in May 2024, the company repurchased approximately $40.2 million of common stock YTD. As of December 31, 2024, approximately $259.8 million remained available under the program.
- Liquidity: The company maintains a $163.8 million borrowing capacity on its asset-based revolving credit facility, which currently has no outstanding balance. Management believes cash flow from operations and existing facilities are sufficient for the next 12 months.
- Risks: Key risks include dependence on third-party manufacturers (one supplier accounts for ~21% of sales), concentration of revenue in top customers (Walmart ~20%, Amazon ~12%), and potential impairment of goodwill and intangible assets if future cash flows decline.
Investor Verification Checklist
- Debt Structure: Verify the impact of the Term B-5 loan repayment on future interest expense and liquidity ratios.
- Supply Chain Resilience: Assess the duration and severity of eye care product shortages and their potential long-term impact on market share.
- Customer Concentration: Monitor sales trends with Walmart and Amazon, which collectively represent over 30% of gross revenues.
- Intangible Assets: Review the valuation assumptions for goodwill ($527 million) and intangible assets ($2.3 billion), which comprise the majority of the balance sheet.
- Share Buyback Pace: Track the utilization of the remaining $259.8 million share repurchase authorization against cash flow generation.